T
Toshiya Katsura
Researcher at Ritsumeikan University
Publications - 119
Citations - 6886
Toshiya Katsura is an academic researcher from Ritsumeikan University. The author has contributed to research in topics: Organic cation transport proteins & Organic anion transporter 1. The author has an hindex of 44, co-authored 119 publications receiving 6368 citations. Previous affiliations of Toshiya Katsura include Kyoto University.
Papers
More filters
Journal ArticleDOI
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters
TL;DR: HMATE1 and hMATE2-K function together as a detoxication system, by mediating the tubular secretion of intracellular ionic compounds across the brush-border membranes of the kidney.
Journal ArticleDOI
Identification and Functional Characterization of a New Human Kidney–Specific H+/Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2
Satohiro Masuda,Tomohiro Terada,Atsushi Yonezawa,Yuko Tanihara,Koshiro Kishimoto,Toshiya Katsura,Osamu Ogawa,Ken-ichi Inui +7 more
TL;DR: Results indicate that hMATE2-K is a new human kidney-specific H+/organic cation antiporter that is responsible for the tubular secretion of cationic drugs across the brush border membranes.
Journal ArticleDOI
Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
Naoko Kimura,Satohiro Masuda,Yuko Tanihara,Harumasa Ueo,Masahiro Okuda,Toshiya Katsura,Ken-ichi Inui +6 more
TL;DR: It is suggested that metformin is a superior substrate for renal OCT2 rather than hepatic OCT1, and renal OCT 2 plays a dominant role for metformIn pharmacokinetics.
Journal ArticleDOI
Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)
TL;DR: Results indicate that cisplatin is a relatively good substrate of hOCT1, hO CT2, and hMATE1, and oxaliplatin has the potential to play predominant roles in the tissue distribution and anticancer effects and/or adverse effects of platinum agent-based chemotherapy.
Journal ArticleDOI
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Yosuke Togashi,Katsuhiro Masago,Satohiro Masuda,Tomoyuki Mizuno,Masahide Fukudo,Yasuaki Ikemi,Yuichi Sakamori,Hiroki Nagai,Young Hak Kim,Toshiya Katsura,Michiaki Mishima +10 more
TL;DR: It is suggested that higher CSF concentration could be achieved with erlotinib and that erlot inib could be more effective for the treatment for CNS metastases, especially leptomeningeal metastases more effective than gefitinib.